Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

EHC vs CHE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EHC Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–5 Matrix Metrics)

EHC Overall Winner 6-Pillar Tally: EHC 4 – 2 CHE Matrix Metrics: EHC 5 – 5 CHE

As of Nov 20, 2026, Encompass Health Corporation (EHC) is the stronger overall head-to-head candidate over Chemed Corporation (CHE) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). EHC carries a Unified Composite Score of 52.0/100 (HOLD) at $133.65 (19.4x Forward P/E, 18.4% operating margin), whereas CHE carries 43.8/100 (HOLD) at $548.59 (19.7x Forward P/E, 14.3% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EHC vs CHE
EHC NYSE Head-to-Head Winner
Encompass Health Corporation Common Stock
Services-Hospitals
$133.65
+1.04% 1D
Market Cap $13.0B
TTM Revenue $6.34B
Forward P/E 19.4x
Beta / 30D Vol -0.10β · 40% Vol
Unified Composite Score
52.0 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 54.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 49.8 · SMA20: $135.78 · SMA50: $128.15
CHE NYSE
Chemed Corporation
Services-Home Health Care Services
$548.59
-0.5% 1D
Market Cap $7.1B
TTM Revenue $2.66B
Forward P/E 19.7x
Beta / 30D Vol 0.11β · 26% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 35.0 Fund 44.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.0% over 20 days), RSI 59
RSI-14: 59.3 · SMA20: $539.63 · SMA50: $520.19

6-Pillar Scorecard Institutional Category Breakdown (EHC 4 – 2 CHE)

Columns: Metric · EHC · CHE
1. Valuation Multiples EHC
Forward P/E 19.4x 19.7x
Trailing P/E 21.2x 26.4x
PEG Ratio 0.41x 1.96x
EV / Revenue 2.5x 2.7x
2. Growth & Scale CHE
Revenue Growth (YoY) +8.9% +10.6%
Earnings Growth (YoY) +21.6% +22.2%
TTM Revenue (USD) $6.34B $2.66B
Market Cap $13.0B $7.1B
3. Profitability & Quality EHC
Gross Margin 44.1% 33.5%
Operating Margin 18.4% 14.3%
Net Profit Margin 10.2% 10.6%
Return on Equity (ROE) 25.1% 29.1%
4. Balance Sheet & Cash Flow CHE
Cash Generation (TTM) $457M $444M EBITDA
Cash Flow Margin 7.2% 16.7% EBITDA Mgn
Net Cash / Leverage $2.73B Net Debt (1.05x D/E) $66.47 Book/Sh · 29.1% ROE
Dividend Yield 0.58% 0.46%
5. Options & Positioning EHC
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 27.0% (8th %ile) 28.2% (10th %ile)
Put/Call OI Skew 0.25x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat EHC
OpEx & R&D Intensity 25.7% of Rev ($1.63B) 19.2% of Rev ($511M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Medical Care Facilities Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EHC (5) vs CHE (5)
Institutional Metric EHC CHE Criterion Row Edge
Market Capitalization
Scale
$13.0B $7.1B Larger Scale EHC
Trailing P/E Ratio
Valuation
21.2x 26.4x Lower Multiple EHC
Forward P/E Ratio
Valuation
19.4x 19.7x Lower Multiple EHC
Revenue Growth (YoY)
Growth
+8.9% +10.6% Higher Growth CHE
Operating Margin (TTM)
Profitability
18.4% 14.3% Higher Margin EHC
Net Profit Margin
Profitability
10.2% 10.6% Higher Margin CHE
Return on Equity (ROE)
Capital Efficiency
25.1% 29.1% Higher ROE CHE
52-Week Range Position
Momentum
80% ($93–$144) 93% ($365–$562) Stronger Trend CHE
Beta / 30D Volatility
Risk Regime
-0.10β · 40% Vol 0.11β · 26% Vol Lower Realized Risk CHE
Unified Institutional Score
Composite Signal
52.0 / 100 (HOLD) 43.8 / 100 (HOLD) Higher Composite EHC
Trailing 12M Revenue (USD)
Operating Scale
$6.34B $2.66B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
44.1% 33.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.41x PEG · 2.5x EV/Rev 1.96x PEG · 2.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$457M ($2.73B Net Debt (1.05x D/E)) $444M EBITDA ($66.47 Book/Sh · 29.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EHC +0.59 pp
EHC: +6.06% · CHE: +5.47%
3M Horizon EHC +9.19 pp
EHC: +10.53% · CHE: +1.34%
6M Horizon EHC +2.47 pp
EHC: +27.33% · CHE: +24.86%
1Y Horizon CHE +8.22 pp
EHC: +19.42% · CHE: +27.64%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EHC vs CHE. Trailing 12-month operating profitability (EHC 18.4% vs CHE 14.3%) and valuation multiples (EHC 19.4x vs CHE 19.7x Forward P/E) are benchmarked directly in Pillar 4 below.

EHC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$6.34B
Gross Margin44.1%
Op. Margin18.4%
ROE / Fwd P/E25.1% · 19.4x
CHE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.66B
Gross Margin33.5%
Op. Margin14.3%
ROE / Fwd P/E29.1% · 19.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EHC CONSOLIDATION
73d in phase · OBV DISTRIBUTION
Current IV 27.0%
IV Percentile 8th %ile
Put/Call OI Skew 0.25x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact EHC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CHE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 28.2%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CHE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EHC Moat Profile Scale & Operating Efficiency Moat
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $13.0B market capitalization and 18.4% operating margin.
OpEx & R&D Reinvestment 25.7% of Rev ($1.63B)
90D Engineering Disclosures 0 Published
CHE Moat Profile Scale & Operating Efficiency Moat
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $7.1B market capitalization and 14.3% operating margin.
OpEx & R&D Reinvestment 19.2% of Rev ($511M)
90D Engineering Disclosures 0 Published

Investor FAQ EHC vs CHE Key Questions & Quantitative Answers

As of Nov 20, 2026, Encompass Health Corporation (EHC) is the stronger overall head-to-head candidate over Chemed Corporation (CHE) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). EHC carries a Unified Composite Score of 52.0/100 (HOLD) at $133.65 (19.4x Forward P/E, 18.4% operating margin), whereas CHE carries 43.8/100 (HOLD) at $548.59 (19.7x Forward P/E, 14.3% operating margin). Technically, EHC sits in a Neutral phase (RSI 49.8, CONSOLIDATION options structure) and CHE sits in a Markup phase (RSI 59.3, UNCLASSIFIED options structure).

CHE leads the Growth & Scale pillar: EHC posts +8.9% YoY revenue growth and +21.6% YoY earnings growth on $6.34B TTM revenue (44.1% gross margin, 18.4% operating margin), compared with CHE at +10.6% YoY revenue growth and +22.2% YoY earnings growth on $2.66B TTM revenue (33.5% gross margin, 14.3% operating margin). On trailing 12-month operating scale, EHC generates $6.34B in USD-normalized revenue versus $2.66B for CHE. In operating R&D and SG&A reinvestment, EHC deploys 25.7% of Rev ($1.63B) (0 90-day corporate R&D disclosures) versus 19.2% of Rev ($511M) (0 disclosures) for CHE.

EHC screens cheaper on headline valuation multiples. EHC trades at 19.4x Forward P/E, 21.2x Trailing P/E, 0.41x PEG, and 2.5x EV/Revenue (7.2% FCF margin), whereas CHE trades at 19.7x Forward P/E, 26.4x Trailing P/E, 1.96x PEG, and 2.7x EV/Revenue (16.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EHC (25.1% ROE) versus CHE (29.1% ROE) capital efficiency.

In options market volatility and institutional positioning, EHC carries 27.0% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.25x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.10β · 40% Vol realized risk). By comparison, CHE carries 28.2% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.11β · 26% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.